clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Dalston MO et al. [Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis--a report of 2 cases]. 1995 Oct-Dec Rev. Soc. Bras. Med. Trop. pmid:8668843
Gélisse P et al. [Carbamazepine and clarithromycin: a clinically relevant drug interaction]. 2007 Rev. Neurol. (Paris) pmid:18033049
Estrada-Gómez RA et al. Helicobacter pylori infection and thrombocytopenia: a single-institution experience in Mexico. 2007 Mar-Apr Rev. Invest. Clin. pmid:17633798
Leal YA et al. A primary Helicobacter pylori infection does not protect against reinfection in children after eradication therapy. 2008 Nov-Dec Rev. Invest. Clin. pmid:19378833
Gutiérrez-Castrellón P et al. Efficacy and safety of clarithromycin in pediatric patients with upper respiratory infections: a systematic review with meta-analysis. 2012 Mar-Apr Rev. Invest. Clin. pmid:22991774
Ramzy I et al. GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. 2016 Rev. Inst. Med. Trop. Sao Paulo pmid:27982354
Picoli SU et al. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. 2014 May-Jun Rev. Inst. Med. Trop. Sao Paulo pmid:24878996
Vianna JS et al. The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori. 2018 Rev. Inst. Med. Trop. Sao Paulo pmid:29972462
Colomina Rodríguez J et al. [Impact of Integrated Model for Rational Use of Antibiotics in a health area (project MIURA)]. Rev. Esp. Salud Publica pmid:20661527
Roche B et al. Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi. 1997 Rev Rhum Engl Ed pmid:9051864
Bronstein JA [National ranking exam. N63. What could fall at the exam?]. 2008 Rev Prat pmid:18506983
Lamouliatte H et al. [Treatment of Helicobacter pylori infection]. 2000 Rev Prat pmid:11019637
Melo-Cristino J et al. The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004. Rev Port Pneumol pmid:16572254
Dautzenberg B [Treatment of atypical mycobacterium infections: current state and therapeutic perspectives]. 1992 Rev Pneumol Clin pmid:1296257
Flores-Gonzalez JC et al. [Etiology, clinical presentation and outcome of severe viral acute childhood encephalitis (ECOVE study)]. 2015 Rev Neurol pmid:26108903
Scheen AJ [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. 1998 Rev Med Liege pmid:9555183
Lutgen N et al. [Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege]. 2001 Rev Med Liege pmid:11256133
Guiot J et al. [Mycobacterium malmoense infection in an immunocompetent patient]. 2009 Jul-Aug Rev Med Liege pmid:19777918
Niang M et al. [Painful nodular lesions]. 1998 Rev Med Interne pmid:9793156
Cinquetti G et al. [Rare complications of Lemierre's syndrome: septic sternoclavicular joint arthritis and cavitating pneumonia]. 2009 Rev Med Interne pmid:19896753
Leclercq V et al. [Avoidable adverse event: carbamazepine encephalopathy when introducing clarithromycine]. 2005 Rev Med Interne pmid:16023268
de Korwin JD [Helicobacter pylori infection and antimicrobial agents resistance]. 2004 Rev Med Interne pmid:14736561
Poiată A et al. [Meropenem activity against staphylococci]. 2005 Jan-Mar Rev Med Chir Soc Med Nat Iasi pmid:16607852
González C et al. [In vitro antimicrobial susceptibility of Helicobacter pylori strains: isolation of strains resistant to clarithromycin]. 2001 Rev Med Chil pmid:11510204
Pavié G J et al. [Assessment of the management of community-acquired pneumonia in adults outpatients]. 2005 Rev Med Chil pmid:16446856
Sánchez H et al. [Compliance with guidelines for the management of community acquired pneumonia at primary health care centers]. 2009 Rev Med Chil pmid:20361133
Alvarez A et al. [Antimicrobial susceptibility of Helicobacter pylori strains isolated in Colombia]. 2009 Rev Med Chil pmid:20011937
Fariña N et al. [Antimicrobial susceptibility of H pylori strains obtained from Paraguayan patients]. 2007 Rev Med Chil pmid:17989858
García-Agudo L et al. [Assessment of in vitro susceptibility to antimicrobials of rapidly growing mycobacteria by E-test]. 2009 Rev Med Chil pmid:19802419
Vallejos C et al. [Prevalence of metronidazole, clarithromycin and tetracycline resistance in Helicobacter pylori isolated from Chilean patients]. 2007 Rev Med Chil pmid:17505573
Job V et al. [Medical-surgical treatment of pulmonary infection with Mycobacterium malmoense]. 2004 Rev Mal Respir pmid:15622347
Dautzenberg B et al. [Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection]. 1994 Rev Mal Respir pmid:8041990
Huet D et al. [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. 2017 Rev Mal Respir pmid:27639948
Camara B et al. [Infection due to Mycobacterium malmoense in an immunocompetent patient]. 2008 Rev Mal Respir pmid:19106910
Schubel K et al. [Pleuropneumonia due to Mycobacterium chelonae]. 2011 Rev Mal Respir pmid:21482339
Dixmier A et al. [Pulmonary infections with Mycobacterium xenopi in patients without HIV infection]. 2007 Rev Mal Respir pmid:17417167
Frija-Masson J et al. [Non-tuberculous mycobacterial infection of a totally implanted perfusion device]. 2015 Rev Mal Respir pmid:25480387
Payen MC et al. [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. 1997 Rev Mal Respir pmid:9496599
Ramon PM et al. [Uveitis, arthralgia and pseudo-jaundice in a HIV seronegative patient due to rifabutin]. 1998 Rev Mal Respir pmid:9608993
Gomez-Abreo D et al. [Chronic necrotizing pulmonary aspergillosis following an infection by Mycobacterium malmoense]. 2012 Rev Mal Respir pmid:22440310
[Zeclar, a new antibiotic (clarithromycin 250 mg from Abbott laboratories]. 1994 Rev Infirm pmid:7652424
Silva FM et al. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. 2001 Jan-Feb Rev Hosp Clin Fac Med Sao Paulo pmid:11378678
Pinto LA et al. Effect of clarithromycin on the cell profile of bronchoalveolar lavage fluid in mice with neutrophil-predominant lung disease. 2004 Rev Hosp Clin Fac Med Sao Paulo pmid:15286828
Souza R et al. Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil. 2002 Jul-Aug Rev Hosp Clin Fac Med Sao Paulo pmid:12244337
Ramírez Ramos A [Treatment of Helicobacter pylori infection: current status]. 1995 Rev Gastroenterol Peru pmid:8520021
Rodríguez W et al. [Omeprazole, amoxicillin and clarithromycin in the treatment of helicobacterpylori, in 7 and 10-day regimens]. 2003 Jul-Sep Rev Gastroenterol Peru pmid:14532918
Velasco Benítez CA and Amorocho Pérez RD [Treatment of gastritis-associated Helicobacter pylori infection in children]. 2002 Apr-Jun Rev Gastroenterol Peru pmid:12098744
Guarner J and Mohar A [The association between Helicobacter pylori and gastric neoplasia. Epidemiologic evidence]. 2000 Oct-Dec Rev Gastroenterol Mex pmid:11464618
Ladrón de Guevara L et al. [Evaluation of the symptomatology and quality of life in functional dyspepsia before and after Helicobacter pylori eradication treatment]. 2004 Oct-Dec Rev Gastroenterol Mex pmid:15765971
Dehesa M et al. [Comparison of 2 schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer]. 1998 Apr-Jun Rev Gastroenterol Mex pmid:10068730
Vakil N Helicobacter pylori treatment: is sequential or quadruple therapy the answer? 2008 Rev Gastroenterol Disord pmid:18641590
Carabias ML et al. [Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study]. 2001 Rev Esp Quimioter pmid:11704772
Gordillo RM et al. [Susceptibility of Streptococcus pyogenes isolates from pharyngeal exudates in Cordoba (Spain)]. 2003 Rev Esp Quimioter pmid:12750758
Cantón E et al. [In vitro susceptibility to antibiotics and the most common Streptococcus pneumoniae serotypes: a multicenter study]. 2005 Rev Esp Quimioter pmid:15915232
Agudo S et al. Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. 2011 Rev Esp Quimioter pmid:21412667
Díaz-Reganon J et al. [Susceptibility of 36 Helicobacter pylori clinical isolates to four first-line antibiotics and virulence factors]. 2006 Rev Esp Quimioter pmid:16688289
Agudo S et al. [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]. 2009 Rev Esp Quimioter pmid:19544100
Orellana MA and Gómez-Lus ML [Which is the best empirical treatment in patients with urethritis?]. 2011 Rev Esp Quimioter pmid:21947096
Vega AE et al. [Detection of resistance to clarithromycin in clinical isolates of Helicobacter pylori from children and adults]. 2003 Rev Esp Quimioter pmid:12750757
Ruiz-Aragón J et al. [Susceptibility to antimicrobial agents of rapidly growing mycobacteria]. 2007 Rev Esp Quimioter pmid:18563216
Guirao-Arrabal E et al. Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. 2016 Rev Esp Quimioter pmid:26888341
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Gálvez-Múgica MA et al. [Meta-analysis of clarithromycin compared to other antibiotics for the treatment of lower respiratory tract infections]. 2003 Rev Esp Quimioter pmid:14961134
Alarcón T et al. [In vitro activity of clarithromycin and metronidazole against Helicobacter pylori in different incubation atmospheres]. 2002 Rev Esp Quimioter pmid:12587039
Rubio-Terrés C et al. [Pharmacoeconomic analysis of community-acquired pneumonia treatment with telithromycin or clarithromycin]. 2003 Rev Esp Quimioter pmid:14702121
Abad-Santos F et al. [Meta-analysis of clarithromycin compared with other antimicrobial drugs in the treatment of upper respiratory tract infections]. 2003 Rev Esp Quimioter pmid:14702124
Alarcón T et al. [In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate]. 2005 Rev Esp Quimioter pmid:16446791
Abasolo Osinaga E et al. [Dispensation and cost of antimicrobials in Spain (1998-2000)]. 2005 Rev Esp Quimioter pmid:16446789
Orden Martínez B et al. [Haemophilus spp. antimicrobial susceptibility in Health Area 6 in Madrid, Spain (2000-2004)]. 2005 Rev Esp Quimioter pmid:16130040
Garza González E et al. [Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status]. 2007 Rev Esp Enferm Dig pmid:17417917
de Artaza Varasa T et al. [Effect of Helicobacter pylori eradication on patients with functional dyspepsia]. 2008 Rev Esp Enferm Dig pmid:19025303
Gisbert JP et al. [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. 1997 Rev Esp Enferm Dig pmid:9221019
Rodrigo Sáez L et al. [The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin]. 1997 Rev Esp Enferm Dig pmid:9115827
Sainz R et al. [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. 1999 Rev Esp Enferm Dig pmid:10601771
Rojas Feria M et al. Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area. 2000 Rev Esp Enferm Dig pmid:11468787
Rodríguez Téllez M et al. Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. 1999 Rev Esp Enferm Dig pmid:10491487
Gisbert JP [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. 1999 Rev Esp Enferm Dig pmid:10231305
González Carro P et al. [Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori]. 1998 Rev Esp Enferm Dig pmid:9780793
Boixeda D et al. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success. 2003 Rev Esp Enferm Dig pmid:12760710
Gisbert JP et al. Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment. 2003 Rev Esp Enferm Dig pmid:12760719
Torres-Debat ME et al. Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistance in strains isolated from patients in Uruguay. 2009 Rev Esp Enferm Dig pmid:20001152
Boixeda de Miquel D [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. 1997 Rev Esp Enferm Dig pmid:9494374
Pérez Mota A et al. Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. 1997 Rev Esp Enferm Dig pmid:9494375
Castro-Fernández M et al. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. 2009 Rev Esp Enferm Dig pmid:19630462
Fernández Martos R et al. Acute psychotic episode secondary to Helicobacter pylori eradication treatment. 2017 Rev Esp Enferm Dig pmid:28071063
Murcia J et al. [Acute myocardial failure in a young man: Q-fever myocarditis]. 2002 Rev Esp Cardiol pmid:12199986
Vallejo Camazón N et al. [Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]. 2002 Rev Esp Cardiol pmid:12199987
Olmos Martínez JM et al. [Definitive treatment of Helicobacter pylori infection in MALT low degree gastric lymphoma]. 2003 Rev Clin Esp pmid:14622518
Alba D et al. [Clarithromycin in the treatment of cerebral toxoplasmosis associated with HIV infection]. 1993 Rev Clin Esp pmid:8516514
Díaz F et al. [Cat-scratch disease. A report of 4 cases and a review of the literature]. 1997 Rev Clin Esp pmid:9102668
Baena Díez JM et al. [Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size]. 1999 Rev Clin Esp pmid:10432821
Gisbert JP et al. [Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?]. 1998 Rev Clin Esp pmid:9844453
Gisbert JP et al. [Role of pantoprazole in the eradicating treatment of Helicobacter pylori]. 1998 Rev Clin Esp pmid:9844458
Asencio Marchante R and Lissen Otero E [Secondary prevention of opportunistic infections in HIV-infected patients]. 2001 Rev Clin Esp pmid:11345612
Cofré Guerra J [Pertussis chemoprophylaxis: a sterile effort?]. 2006 Rev Chilena Infectol pmid:16462967
Morfín Maciel BM and Castillo Ramos HA [Reactive polyarthritis and painful dermatographism caused by Helicobacter pylori]. 2002 May-Jun Rev Alerg Mex pmid:12190006
Matieli LC et al. Mycobacterium abscessus endophthalmitis: treatment dilemma and review of the literature. 2006 Retina (Philadelphia, Pa.) pmid:16963860
Unal M et al. Ocular toxicity of intravitreal clarithromycin. 1999 Retina (Philadelphia, Pa.) pmid:10546942
Ding FM et al. Low-dose clarithromycin therapy modulates CD4(+) T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection. 2012 Respirology pmid:22404374
Kikuchi E et al. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. 2008 Respirology pmid:18339019